Pre-treatment testosterone levels: Significance in androgen deprivation therapy

D. Hickey, B. Todd, M. S. Soloway

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

From June 1982 to February 1985, 53 patients with stage D2 carcinoma of the prostate confirmed by tissue biopsy, elevated prostatic acid phosphatase and a positive bone scan were initiated on androgen deprivation therapy. Before commencement of treatment all patients underwent determination of serum testosterone levels at 8 a.m. Of the patients 23 received 200 mcg buserelin per day, 17 received 1 mg diethylstilbestrol 3 times daily, 6 received 40 mg megestrol acetate 4 times daily, 2 received 1 mg leuprolide per day and 5 underwent bilateral orchiectomy. Evaluation of the best response in each patient revealed 3 (6 per cent) complete and 17 (32 per cent) partial responses, while 22 patients (41 per cent) remained stable and 11 (21 per cent) had progression. Pre-treatment serum testosterone levels ranged from 150 to 879 ng per dl. The mean serum testosterone level in patients having a complete response was 524 ± 18.04 ng per dl. The mean in the progression group was 279.4 ± 110.1 ng per dl. This difference was not statistically significant owing to the large standard deviation in the progression group. However, of the 15 patients who had a pre-treatment serum testosterone level of more than 500 ng per dl only 1 (7 per cent) had progression. None of the patients whose pre-treatment testosterone level was less than 200 ng per dl had objective tumor regression. Our study suggests that pre-treatment serum testosterone levels may predict the probability of a satisfactory response to androgen deprivation therapy.

Original languageEnglish
Pages (from-to)1038-1040
Number of pages3
JournalJournal of Urology
Volume136
Issue number5
StatePublished - Dec 1 1986
Externally publishedYes

Fingerprint

Androgens
Testosterone
Serum
Therapeutics
Megestrol Acetate
Buserelin
Leuprolide
Diethylstilbestrol
Orchiectomy
Prostate
Carcinoma
Biopsy
Bone and Bones
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Hickey, D., Todd, B., & Soloway, M. S. (1986). Pre-treatment testosterone levels: Significance in androgen deprivation therapy. Journal of Urology, 136(5), 1038-1040.

Pre-treatment testosterone levels : Significance in androgen deprivation therapy. / Hickey, D.; Todd, B.; Soloway, M. S.

In: Journal of Urology, Vol. 136, No. 5, 01.12.1986, p. 1038-1040.

Research output: Contribution to journalArticle

Hickey, D, Todd, B & Soloway, MS 1986, 'Pre-treatment testosterone levels: Significance in androgen deprivation therapy', Journal of Urology, vol. 136, no. 5, pp. 1038-1040.
Hickey, D. ; Todd, B. ; Soloway, M. S. / Pre-treatment testosterone levels : Significance in androgen deprivation therapy. In: Journal of Urology. 1986 ; Vol. 136, No. 5. pp. 1038-1040.
@article{8ec874ece41245ffad68e613683b1be2,
title = "Pre-treatment testosterone levels: Significance in androgen deprivation therapy",
abstract = "From June 1982 to February 1985, 53 patients with stage D2 carcinoma of the prostate confirmed by tissue biopsy, elevated prostatic acid phosphatase and a positive bone scan were initiated on androgen deprivation therapy. Before commencement of treatment all patients underwent determination of serum testosterone levels at 8 a.m. Of the patients 23 received 200 mcg buserelin per day, 17 received 1 mg diethylstilbestrol 3 times daily, 6 received 40 mg megestrol acetate 4 times daily, 2 received 1 mg leuprolide per day and 5 underwent bilateral orchiectomy. Evaluation of the best response in each patient revealed 3 (6 per cent) complete and 17 (32 per cent) partial responses, while 22 patients (41 per cent) remained stable and 11 (21 per cent) had progression. Pre-treatment serum testosterone levels ranged from 150 to 879 ng per dl. The mean serum testosterone level in patients having a complete response was 524 ± 18.04 ng per dl. The mean in the progression group was 279.4 ± 110.1 ng per dl. This difference was not statistically significant owing to the large standard deviation in the progression group. However, of the 15 patients who had a pre-treatment serum testosterone level of more than 500 ng per dl only 1 (7 per cent) had progression. None of the patients whose pre-treatment testosterone level was less than 200 ng per dl had objective tumor regression. Our study suggests that pre-treatment serum testosterone levels may predict the probability of a satisfactory response to androgen deprivation therapy.",
author = "D. Hickey and B. Todd and Soloway, {M. S.}",
year = "1986",
month = "12",
day = "1",
language = "English",
volume = "136",
pages = "1038--1040",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Pre-treatment testosterone levels

T2 - Significance in androgen deprivation therapy

AU - Hickey, D.

AU - Todd, B.

AU - Soloway, M. S.

PY - 1986/12/1

Y1 - 1986/12/1

N2 - From June 1982 to February 1985, 53 patients with stage D2 carcinoma of the prostate confirmed by tissue biopsy, elevated prostatic acid phosphatase and a positive bone scan were initiated on androgen deprivation therapy. Before commencement of treatment all patients underwent determination of serum testosterone levels at 8 a.m. Of the patients 23 received 200 mcg buserelin per day, 17 received 1 mg diethylstilbestrol 3 times daily, 6 received 40 mg megestrol acetate 4 times daily, 2 received 1 mg leuprolide per day and 5 underwent bilateral orchiectomy. Evaluation of the best response in each patient revealed 3 (6 per cent) complete and 17 (32 per cent) partial responses, while 22 patients (41 per cent) remained stable and 11 (21 per cent) had progression. Pre-treatment serum testosterone levels ranged from 150 to 879 ng per dl. The mean serum testosterone level in patients having a complete response was 524 ± 18.04 ng per dl. The mean in the progression group was 279.4 ± 110.1 ng per dl. This difference was not statistically significant owing to the large standard deviation in the progression group. However, of the 15 patients who had a pre-treatment serum testosterone level of more than 500 ng per dl only 1 (7 per cent) had progression. None of the patients whose pre-treatment testosterone level was less than 200 ng per dl had objective tumor regression. Our study suggests that pre-treatment serum testosterone levels may predict the probability of a satisfactory response to androgen deprivation therapy.

AB - From June 1982 to February 1985, 53 patients with stage D2 carcinoma of the prostate confirmed by tissue biopsy, elevated prostatic acid phosphatase and a positive bone scan were initiated on androgen deprivation therapy. Before commencement of treatment all patients underwent determination of serum testosterone levels at 8 a.m. Of the patients 23 received 200 mcg buserelin per day, 17 received 1 mg diethylstilbestrol 3 times daily, 6 received 40 mg megestrol acetate 4 times daily, 2 received 1 mg leuprolide per day and 5 underwent bilateral orchiectomy. Evaluation of the best response in each patient revealed 3 (6 per cent) complete and 17 (32 per cent) partial responses, while 22 patients (41 per cent) remained stable and 11 (21 per cent) had progression. Pre-treatment serum testosterone levels ranged from 150 to 879 ng per dl. The mean serum testosterone level in patients having a complete response was 524 ± 18.04 ng per dl. The mean in the progression group was 279.4 ± 110.1 ng per dl. This difference was not statistically significant owing to the large standard deviation in the progression group. However, of the 15 patients who had a pre-treatment serum testosterone level of more than 500 ng per dl only 1 (7 per cent) had progression. None of the patients whose pre-treatment testosterone level was less than 200 ng per dl had objective tumor regression. Our study suggests that pre-treatment serum testosterone levels may predict the probability of a satisfactory response to androgen deprivation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023010411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023010411&partnerID=8YFLogxK

M3 - Article

C2 - 3095566

AN - SCOPUS:0023010411

VL - 136

SP - 1038

EP - 1040

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -